In re: Baldwin et al.

Serial No. 08/959,160

Filed: 28 October 1997

Page 2 of 8

In the Claims:

1. (currently amended) A method of enhancing the cytotoxic effects of an antineoplastic

chemotherapeutic agent, comprising administering to a mammalian subject in need of such

therapy said antineoplastic chemotherapeutic agent a therapeutically effective amount of NF-kB

inhibitor in conjunction with the administration of the chemotherapeutic agent, whereby the

cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur

in the absence of NF-kB inhibitor;

wherein said NF-κB inhibitor is a proteasome inhibitor;

and wherein said antineoplastic chemotherapeutic agent is an anthracyclene antibiotic.

2. (Original) A method according to claim 1 wherein said NF-kB inhibitor is administered

simultaneously with said chemotherapeutic agent.

3. (Previously Presented) The method of claim 1 where said chemotherapeutic agent is

selected from the group consisting of daunorubicin, doxorubicin, mitoxantraone, and bisanthrene

4. Cancelled.

5. Cancelled.

6. (currently amended) A method of enhancing chemotherapeutic cytotoxicity in a

mammalian subject treated with an antineoplastic chemotherapeutic agent, comprising

administering to the mammalian subject a therapeutically effective amount of an NF-kB inhibitor

in conjunction with the administration of the chemotherapeutic agent, whereby the cytotoxic

effect of said chemotherapeutic agent is increased compared to that which would occur in the

absence of said NF-kB inhibitor;

wherein said NF-kB inhibitor is a proteasome inhibitor;

In re: Baldwin et al.

Serial No. 08/959,160

Filed: 28 October 1997

Page 3 of 8

and wherein said chemotherapeutic agent is an anthracyclene antibiotic.

7. (Original) A method according to claim 6 wherein said NF-κB inhibitor is administered simultaneously with said chemotherapeutic agent.

8. (Previously Presented) A method according to claim 6 wherein said chemotherapeutic agent is selected from the group consisting of daunorubicin, doxorubicin, mitoxantraone, and bisanthrene.

- 9. Cancelled.
- 10. Cancelled.
- 11. Cancelled.
- 12. Cancelled.
- 13. Cancelled.

14. (currently amended) A method of treating a tumor in a mammalian subject with a chemotherapeutic agent, the improvement comprising administering an effective amount of an NF-κB inhibitor in conjunction with said chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of said NF-κB inhibitor;

wherein said NF-κB inhibitor is a proteasome inhibitor; and wherein said chemotherapeutic agent is an anthracyclene antibiotic.

15. (currently amended) A method of treating a mammalian subject receiving a chemotherapeutic agent for the treatment of a neoplastic growth, the improvement comprising

In re: Baldwin et al.

Serial No. 08/959,160

Filed: 28 October 1997

Page 4 of 8

administering an effective amount of an NF-kB inhibitor to the subject in conjunction with said

chemotherapeutic agent, wherein the effect is to increase the cytotoxic effects of said

chemotherapeutic agent;

wherein said NF-κB inhibitor is a proteasome inhibitor;

and wherein said chemotherapeutic agent is an anthracyclene antibiotic.

16. (currently amended) A method of increasing the cytotoxicity of a chemotherapeutic

agent administered to a mammalian subject for the treatment of a neoplastic growth, comprising

administering an effective amount of an NF-kB inhibitor to said subject in conjunction with said

chemotherapeutic agent, wherein the effect is to increase the cytotoxic effects of said

chemotherapeutic agent;

wherein said NF-κB inhibitor is a proteasome inhibitor;

and wherein said chemotherapeutic agent is an anthracyclene antibiotic.

17. Cancelled.

18. Cancelled.

19. Cancelled.


20. Cancelled.

21. Cancelled.

22. Cancelled.

23. Cancelled.

24. Cancelled.





- 26. Cancelled.
- 27. Cancelled.
- 28. Cancelled.
- 29. (Previously Presented) The method of claim 16, wherein said chemotherapeutic agent is doxorubicin.
- 30. (Previously Presented) The method of claim 16, wherein said neoplastic growth is breast cancer.
- 31. (Previously Presented) The method of claim 16, wherein said chemotherapeutic agent is doxorubicin and said neoplastic growth is breast cancer.